SMC rejects Rupafin, Axorid and Depodur

The following drugs have been rejected by the Scottish Medicines Consortium (SMC) for use within NHS Scotland, as a result of absent or insufficient submissions from manufacturers:

  • Rupatadine (Rupafin) for allergic rhinitis and chronic idiopathic urticaria.
  • Ketoprofen/omeprazole (Axorid) for rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients with a history or risk of NSAID-associated gastrointestinal ulceration or erosion.
  • Extended-release epidural morphine (Depodur) for relief of post-operative pain following major orthopaedic, abdominal or pelvic surgery.

The drugs may be subject to re-appraisal.

Further information: SMC

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Boxes and bottles of medicines on shelves in a pharmacy dispensary.

Medicine shortages increasing, say GPs

Medicine shortages have worsened during the past year,...

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...